Polycomb Repressive Complex 2 Modulation through the Development of EZH2-EED Interaction Inhibitors and EED Binders

Area of Science:

• Epigenetics
• Molecular Biology
• Medicinal Chemistry

Background:

• Epigenetics is a rapidly advancing field.
• Targeting Enhancer of Zeste Homolog 2 (EZH2) has shown promise in cancer therapy, with tazemetostat recently gaining FDA approval for lymphoma.
• Direct EZH2 inhibition is effective only in a subset of cancers.

Purpose of the Study:

• To review recent developments in targeting the PRC2 complex.
• To explore novel strategies focusing on EZH2-EED protein-protein interactions and EED inhibitors.
• To provide a medicinal chemist's perspective on emerging PRC2 modulators.

Main Methods:

• Review of recent scientific literature on PRC2 modulators.
• Analysis of drug development targeting EZH2 and its interactions.
• Evaluation of biological activities of novel PRC2 inhibitors.

Main Results:

• Direct EZH2 inhibition has limitations in cancer treatment efficacy.
• Targeting the EZH2-EED interaction offers a new approach to modulate PRC2 activity.
• Development of EED inhibitors represents a promising indirect modulation strategy.

Conclusions:

• Disrupting PRC2 complex integrity is a viable therapeutic strategy.
• EZH2-EED interaction inhibitors and EED inhibitors are emerging as important drug classes.
• These novel modulators hold potential for broader applications in cancer therapy.